N-(benzenesulfonyl)-2-[5-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]indol-1-yl]acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-(benzenesulfonyl)-2-[5-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]indol-1-yl]acetamide
• 化学式: C₂₈H₂₂F₃N₃O₅S
• 分子量: 569.6
• InChiKey: FOYHOARXQDRBKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  40
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  112
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• Indole derivatives as ppar modulators
  申请人：Conner Eugene Scott

  公开号：US20060166983A1

  公开（公告）日：2006-07-27

  The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in (I) are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.

  本发明涉及一种通过使用结构式(I)的化合物调节过氧化物酶体增殖物激活受体进行治疗的方法。式(I)中的变量在此定义。还包括化合物、制备化合物的方法和制药组合物。本发明的化合物被认为对治疗和预防X综合症、2型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉粥样硬化以及其他与X综合症和心血管疾病有关的疾病有效。
• INDOLE DERIVATIVES AS PPAR MODULATORS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1581491A1

  公开（公告）日：2005-10-05
• [EN] INDOLE DERIVATIVES AS PPAR MODULATORS<br/>[FR] DÉRIVÉS D'INDOLE UTILISÉS COMME MODULATEURS
  申请人：LILLY CO ELI

  公开号：WO2004092131A1

  公开（公告）日：2004-10-28

  The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in (I) are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.